Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viroblock SA

www.viroblock.com

Latest From Viroblock SA

Start-Up Execs On The Move, April 2012

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device

Start-Up Previews (11/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Look For A Place In Coming Hepatitis C Combo Regimens." features profiles of AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus. Plus these Start-Ups Across Health Care: Arineta, HemoShear, Hygieia and Silver Bullet Therapeutics.

Start-Ups Look For Places In Future HCV Combo Regimens

With more than 50 drugs in development for hepatitis C, what comes next after first-generation protease inhibitors and what opportunity might there be for small start-up firms in a space where so many Big Pharma and specialty pharma companies are active? Approvals of direct-acting antiviral therapies are just around the corner in hepatitis C, and smaller companies are looking to provide parts of the puzzle in next-generation drug cocktails that will tackle the growing disease. However, in order for small companies to succeed in this highly competitive space they'll need highly differentiated products. START-UP profiles AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus.
BioPharmaceutical

Viroblock SA

Viroblock SA is taking a decidedly pragmatic approach to commercializing a solution of two ingredients "generally recognized as safe" that when combined appear to inactivate viruses. The company is looking to leverage a liquid mixture that contains liposomes and cyclodextrin, a chemical frequently harnessed for its ability to bond with hydrophobic substances to fight viral infections.
BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Liposomes
  • Medical Devices
    • Infection Control-Sterilization
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Viroblock SA
  • Senior Management
  • Jamie Paterson, PhD, CEO
    Thierry Pelet, PhD, CSO
  • Contact Info
  • Viroblock SA
    Phone: (41) 022 884 8346
    Chemin des Aulx 18
    Plan-les-Ouates (Geneva), 1228
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register